A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers.

@article{Wu2004ACI,
  title={A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers.},
  author={George C H Wu and Arturo Wadgymar and Gordon X Wong and Robert Ting and Bharat Nathoo and David C. Mendelssohn and Sanjay Pandeya and Daniel Sapir and Paul Tam},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2004},
  volume={44 2},
  pages={264-9}
}
BACKGROUND Epoetin alfa (Eprex*; Johnson & Johnson, Manati, PR) has been used successfully to correct the anemia of chronic renal failure for more than 12 years. Anti-erythropoietin (anti-EPO) antibodies have been reported in a small number of patients, resulting in a blood disorder, pure red cell aplasia (PRCA). To evaluate the utility of a large-scale… CONTINUE READING